Received Sep 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | — | — |
Extra Vaccine Administered (Trumenba); This non-serious case was reported by a physician via call center representative and described the occurrence of extra dose administered in a patient who received Men B NVS (Bexsero) for prophylaxis. Previously administered products included Bexsero (patient had 1st dose on unknown date). On 19-MAR-2025, the patient received the 2nd dose of Bexsero. On 08-JAN-2025, an unknown time after receiving Bexsero, the patient experienced extra dose administered (Verbatim: Extra Vaccine Administered (Trumenba)). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 19-AUG-2025 Child B received 2nd dose of Bexsero on March 19, 2025. reporter asked if need to administer a 3rd dose of Bexsero or are the 2 doses sufficient for immunogenicity. This case is linked with US2025106910 reported by same reporter.; Sender's Comments: US-GSK-US2025106910:same reporter different patient